Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Suppressing cancer with a master control gene

ATOH1 gene could be targeted to switch off cancer

Starting with the fruit fly and then moving into mice and humans, researchers in Belgium, have shown that expression of the same gene suppresses cancer in all three organisms. Reciprocally, switching off the gene, called ATO in flies and ATOH1 in mammals, leads to cancer. The authors show there is a good chance that the gene can be switched on again with a drug. They report their findings in two papers in the online open access journal PLoS Biology.

During the human growth from a fertilised egg to adult cell divisions become increasingly differentiated from each other, until in an adult almost all cells are highly specialized to perform a specific function – skin cells, liver cells, eye lens cells, nerve cells, etc. Cancer cells are less differentiated than normal cells, leading to the hypothesis that the final steps of differentiation prevent cells from becoming cancerous.

New work conducted by Wouter Bossuyt, Bassem Hassan, and colleagues at VIB Vesalius Research Center and Katholieke University, Leuven has tested this theory. They demonstrate that in the fruit fly, master control genes steering the specialisation step inhibit tumour formation.

In collaboration with colleagues from the United States, they have shown that loss of one of those genes, Atonal homolog 1 (ATOH1), causes colon cancer in mice. The gene regulates the last step in the specialisation to epithelial cells of the colon. Humans with colon cancer frequently have an inactivated ATOH1 gene, the researchers show.

The researchers could reactivate the gene in human colon cancer cells grown in culture. This caused the tumour cells to stop growing and commit suicide. This exciting, but preliminary, result suggests that it may be possible to switch the gene back on in living patients to target their cancers. Taking this work in the test tube and using it to develop a therapy is an exciting but complicated challenge. Therefore, more work will be required to further understand the role of ATOH1 in suppressing cancer formation.

 

 

1st Paper: 

Bossuyt W, De Geest N, Aerts S, Leenaerts I, Marynen P, et al. (2009) The Atonal proneural transcription factor links differentiation and tumor formation in Drosophila. PLoS Biol 7(2): e1000040.

doi:10.1371/journal.pbio.1000040

 

2nd paper:

Bossuyt W, Kazanjian A, De Geest N, Van Kelst S, De Hertogh G, et al. (2009) Atonal homolog 1 is a tumor suppressor gene. PLoS Biol 7(2): e1000039.

doi:10.1371/journal.pbio.1000039

 

 

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation